5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation

Füller,Mathias; Klein,Miriam; Schmidt,Eva; Rohde,Christian; Göllner,Stefanie; Schulze,Isabell; Qianli,Jiang; Berdel,Wolfgang E.; Edemir,Bayram; Müller-Tidow,Carsten; Tschanter,Petra

doi:10.3892/ijo.2014.2792

5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation

Authors:
- Mathias Füller
- Miriam Klein
- Eva Schmidt
- Christian Rohde
- Stefanie Göllner
- Isabell Schulze
- Jiang Qianli
- Wolfgang E. Berdel
- Bayram Edemir
- Carsten Müller-Tidow
- Petra Tschanter
View Affiliations

Affiliations: Department of Medicine A, Hematology and Oncology, University of Münster, Münster, Germany, Department of Medicine IV, Hematology and Oncology, University of Halle, Halle, Germany
Published online on: December 10, 2014 https://doi.org/10.3892/ijo.2014.2792
Pages: 1192-1204

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The DNA methyltransferase (DNMT) inhibitory drugs such as 5-azacytidine induce DNA hypomethylation by inhibiting DNA methyltransferases. While clinically effective, DNMT inhibitors are not curative. A combination with cytotoxic drugs might be beneficial, but this is largely unexplored. In the present study, we analyzed potential synergisms between cytotoxic drugs and 5-azacytidine in acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC) cells. Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. Drug interaction and potential synergism was analyzed according to the Chou-Talalay algorithm. Further analyses were based on soft agar colony formation assays, active caspase-3 staining and BrdU incorporation flow cytometry. To identify effects on DNA methylation patterns, we performed genome wide DNA methylation analysis using 450K bead arrays. Azacytidine at low doses was synergistic with cytotoxic drugs in NSCLC and in AML cell lines. Simultaneous exposure to 5-azacytidine with cytotoxic drugs showed strong synergistic activity. In colony formation assays these synergisms were repeatedly verified for 5-azacytidine (25 nM) with low doses of anticancer agents. 5-azacytidine neither affected the cell cycle nor increased apoptosis. 450K methylation bead arrays revealed 1,046 CpG sites in AML and 1,778 CpG sites in NSCLC cells with significant DNA hypomethylation (24-h exposure) to 5-azacytidine combined with the cytotoxic drugs. These CpG-sites were observed in the candidate tumor-suppressor genes MGMT and THRB. Additional incubation time after 24-h treatment led to a 4.1-fold increase of significant hypomethylated CpG-sites in NSCLC cells. These results suggest that the addition of DNA demethylating agents to cytotoxic anticancer drugs exhibits synergistic activity in AML and NSCLC. Dysregulation of an equilibrium of DNA methylation in cancer cells might increase the susceptibility for cytotoxic drugs.

View Figures

View References

1	SEER cancer statistics review (CSR) 1975–2010 [Internet]. June 14–2013, cited March 6th 2014]. Available from: http://seer.cancer.gov/statfacts/.
2	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
3	Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
4	Jones PA and Baylin SB: The epigenomics of cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
5	Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW and Ehrlich M: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11:6883–6894. 1983. View Article : Google Scholar : PubMed/NCBI
6	Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525–4530. 1995.PubMed/NCBI
7	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
8	Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
9	Pradhan S, Bacolla A, Wells RD and Roberts RJ: Recombinant human DNA (cytosine-5) methyltransferase. I expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem. 274:33002–33010. 1999. View Article : Google Scholar : PubMed/NCBI
10	Bird A: DNA methylation patterns and epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar : PubMed/NCBI
11	Okano M, Xie S and Li E: Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 19:219–220. 1998. View Article : Google Scholar : PubMed/NCBI
12	Okano M, Bell DW, Haber DA and Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 99:247–257. 1999. View Article : Google Scholar : PubMed/NCBI
13	Ehrlich M: DNA hypomethylation in cancer cells. Epigenomics. 1:239–259. 2009. View Article : Google Scholar
14	Damiani LA, Yingling CM, Leng S, Romo PE, Nakamura J and Belinsky SA: Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res. 68:9005–9014. 2008. View Article : Google Scholar : PubMed/NCBI
15	Hollenbach PW, Nguyen AN, Brady H, et al: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 5:e90012010. View Article : Google Scholar : PubMed/NCBI
16	Cihak A: Biological effects of 5-azacytidine in eukaryotes. Oncology. 30:405–422. 1974. View Article : Google Scholar : PubMed/NCBI
17	Tsai HC, Li H, Van Neste L, et al: Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 21:430–446. 2012. View Article : Google Scholar : PubMed/NCBI
18	Hagemann S, Heil O, Lyko F and Brueckner B: Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 6:e173882011. View Article : Google Scholar : PubMed/NCBI
19	Hascher A, Haase AK, Hebestreit K, et al: DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes. Clin Cancer Res. 20:814–812. 2014. View Article : Google Scholar
20	Flotho C, Claus R, Batz C, et al: The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 23:1019–1028. 2009. View Article : Google Scholar : PubMed/NCBI
21	Vidaza. EPAR - product information (Internet). January 3–2014, cited February 6, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000978/WC500050239.pdf.
22	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
23	Festuccia C, Gravina GL, D’Alessandro AM, et al: Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer. 16:401–413. 2009. View Article : Google Scholar : PubMed/NCBI
24	Tikoo K, Ali IY, Gupta J and Gupta C: 5-azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. Toxicol Lett. 191:158–166. 2009. View Article : Google Scholar : PubMed/NCBI
25	Francia G, Green SK, Bocci G, et al: Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. Mol Cancer Ther. 4:1484–1494. 2005. View Article : Google Scholar : PubMed/NCBI
26	Efferth T, Futscher BW and Osieka R: 5-azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs. Blood Cells Mol Dis. 27:637–648. 2001. View Article : Google Scholar : PubMed/NCBI
27	Kong XB, Tong WP and Chou TC: Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. Mol Pharmacol. 39:250–257. 1991.PubMed/NCBI
28	Asano T, Nakamura K, Fujii H, et al: Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation. Br J Cancer. 92:1486–1492. 2005. View Article : Google Scholar : PubMed/NCBI
29	Murakami T, Li X, Gong J, Bhatia U, Traganos F and Darzynkiewicz Z: Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res. 55:3093–3098. 1995.PubMed/NCBI
30	Cross M and Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell. 64:271–280. 1991. View Article : Google Scholar : PubMed/NCBI
31	Khan R, Schmidt-Mende J, Karimi M, et al: Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol. 36:149–157. 2008. View Article : Google Scholar : PubMed/NCBI
32	Abbruzzese JL and Frost P: Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin. Cancer Chemother Pharmacol. 30:31–36. 1992. View Article : Google Scholar
33	Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G and Issa JP: Effect of AraC and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 13:4225–4232. 2007. View Article : Google Scholar : PubMed/NCBI
34	Issa JP and Kantarjian HM: Targeting DNA methylation. Clin Cancer Res. 15:3938–3946. 2009. View Article : Google Scholar : PubMed/NCBI
35	Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60:6039–6044. 2000.PubMed/NCBI
36	Gius D, Cui H, Bradbury CM, et al: Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell. 6:361–371. 2004. View Article : Google Scholar : PubMed/NCBI
37	Gu C, Lu J, Cui T, et al: Association between MGMT promoter methylation and non-small cell lung cancer: a meta-analysis. PLoS One. 8:e726332013. View Article : Google Scholar : PubMed/NCBI
38	Su Y, Xu H, Xu Y, Yu J, Xian Y and Luo Q: Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes. Hematology. 17:41–46. 2012. View Article : Google Scholar : PubMed/NCBI
39	Dmitriev AA, Kashuba VI, Haraldson K, et al: Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics. 7:502–513. 2012. View Article : Google Scholar : PubMed/NCBI
40	Dunwell TL, Hesson LB, Pavlova T, et al: Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics. 4:185–193. 2009. View Article : Google Scholar : PubMed/NCBI
41	Addou-Klouche L, Adelaide J, Finetti P, et al: Loss, mutation and deregulation of L3MBTL4 in breast cancers. Mol Cancer. 9:213PubMed/NCBI
42	Chen SC, Lin CY, Chen YH, et al: Aberrant promoter methylation of EDNRB in lung cancer in Taiwan. Oncol Rep. 15:167–172. 2006.
43	Toyooka KO, Toyooka S, Virmani AK, et al: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 61:4556–4560. 2001.PubMed/NCBI
44	Finger EC, Turley RS, Dong M, How T, Fields TA and Blobe GC: TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis. 29:528–535. 2008. View Article : Google Scholar : PubMed/NCBI
45	Deng G, Nguyen A, Tanaka H, et al: Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int J Cancer. 118:2999–3005. 2006. View Article : Google Scholar : PubMed/NCBI
46	Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene. 21:5400–5413. 2002. View Article : Google Scholar : PubMed/NCBI
47	Shang D, Liu Y, Matsui Y, Ito N, Nishiyama H, Kamoto T and Ogawa O: Demethylating agent 5-aza-2′-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin. Urology. 71:1220–1225. 2008. View Article : Google Scholar : PubMed/NCBI
48	Eklund H, Uhlin U, Farnegardh M, Logan DT and Nordlund P: Structure and function of the radical enzyme ribonucleotide reductase. Prog Biophys Mol Biol. 77:177–268. 2001. View Article : Google Scholar
49	Lu AG, Feng H, Wang PX, Han DP, Chen XH and Zheng MH: Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair. World J Gastroenterol. 18:4704–4713. 2012. View Article : Google Scholar : PubMed/NCBI
50	Morikawa T, Hino R, Uozaki H, et al: Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748. 2010. View Article : Google Scholar : PubMed/NCBI
51	Klisovic RB, Blum W, Wei X, et al: Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res. 14:3889–3895. 2008. View Article : Google Scholar : PubMed/NCBI
52	Aimiuwu J, Wang H, Chen P, et al: RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 119:5229–5238. 2012. View Article : Google Scholar : PubMed/NCBI
53	Rauscher F III and Cadman E: Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity. Cancer Res. 43:2688–2693. 1983.PubMed/NCBI
54	Gray SG, Baird AM, O’Kelly F, et al: Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyl-transferase inhibitor. Int J Mol Med. 30:1505–1511. 2012.PubMed/NCBI
55	Smith SL and Douglas KT: Stereoselective, strong inhibition of ribonucleotide reductase from E. coli by cisplatin. Biochem Biophys Res Commun. 162:715–723. 1989. View Article : Google Scholar : PubMed/NCBI
56	Ellerhorst JA, Frost P, Abbruzzese JL, Newman RA and Chernajovsky Y: 2′-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypo-methylation. Br J Cancer. 67:209–215. 1993. View Article : Google Scholar : PubMed/NCBI
57	Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM and Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 2:521–530. 1996.PubMed/NCBI